메뉴 건너뛰기




Volumn 103, Issue 2, 1997, Pages 92-99

The prevention of early postmenopausal bone loss by cyclical etidronate therapy: A 2-year, double-blind, placebo-controlled study

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; ETIDRONIC ACID;

EID: 0030753790     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(97)00019-3     Document Type: Article
Times cited : (81)

References (33)
  • 1
    • 0028130605 scopus 로고
    • The use of bisphosphonates in osteoporosis
    • Fleisch H. The use of bisphosphonates in osteoporosis. Br J Clin Pract. 1994;48:323-326.
    • (1994) Br J Clin Pract , vol.48 , pp. 323-326
    • Fleisch, H.1
  • 2
    • 0000192287 scopus 로고
    • Bisphosphonates: Structural-activity relationships and therapeutic implications
    • Heersche JNM, Kanis J (eds.) Amsterdam: Elsevier
    • Geddes AD, D'Souza SM, Ebetino FH, Ibbotson KJ. Bisphosphonates: structural-activity relationships and therapeutic implications. Heersche JNM, Kanis J (eds.) In: Bone and Mineral Research/8. Amsterdam: Elsevier, 1995:265-306.
    • (1995) Bone and Mineral Research/8 , pp. 265-306
    • Geddes, A.D.1    D'Souza, S.M.2    Ebetino, F.H.3    Ibbotson, K.J.4
  • 4
    • 0027378596 scopus 로고
    • The role of bisphosphonates in the prevention and treatment of osteoporosis
    • Papapoulos SE. The role of bisphosphonates in the prevention and treatment of osteoporosis. Am J Med. 1993;95:48S-52S.
    • (1993) Am J Med , vol.95
    • Papapoulos, S.E.1
  • 5
    • 0027166137 scopus 로고
    • Bisphosphonates in the treatment of metabolic bone diseases
    • Rodan GA, Balena R. Bisphosphonates in the treatment of metabolic bone diseases. Ann J Med. 1993;25:373-378.
    • (1993) Ann J Med , vol.25 , pp. 373-378
    • Rodan, G.A.1    Balena, R.2
  • 6
    • 0029055554 scopus 로고
    • Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: Four-year randomized study
    • Wimalawansa SJ. Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: four-year randomized study. Am J Med. 1995;99:36-42.
    • (1995) Am J Med , vol.99 , pp. 36-42
    • Wimalawansa, S.J.1
  • 7
    • 4243969763 scopus 로고
    • Alendronate prevents bone loss at the spine and hip in recently postmenopausal women
    • Eisman JA, Christiansen C, McClung M, et al. Alendronate prevents bone loss at the spine and hip in recently postmenopausal women. J Bone Miner Res. 1995;10(suppl):S176.
    • (1995) J Bone Miner Res , vol.10 , Issue.SUPPL.
    • Eisman, J.A.1    Christiansen, C.2    McClung, M.3
  • 8
    • 0024847728 scopus 로고
    • Prevention of postmenopausal bone loss by tiludronate
    • Reginster JY, Lecart MP, Deroisy R, et al. Prevention of postmenopausal bone loss by tiludronate. Lancet. 1989;ii:1469-1471.
    • (1989) Lancet , vol.2 , pp. 1469-1471
    • Reginster, J.Y.1    Lecart, M.P.2    Deroisy, R.3
  • 9
    • 0027529964 scopus 로고
    • Bone density at various sites for prediction of hip fractures
    • Cummings SR, Black DM, Nevitt MC, et al. Bone density at various sites for prediction of hip fractures. Lancet 1993;341:72-75.
    • (1993) Lancet , vol.341 , pp. 72-75
    • Cummings, S.R.1    Black, D.M.2    Nevitt, M.C.3
  • 10
    • 0024458249 scopus 로고
    • Baseline measurement of bone mass predicts fracture in white women
    • Hui SL, Slemenda CW, Johnston CC. Baseline measurement of bone mass predicts fracture in white women. Ann Intern J Med. 1989;111:355-361.
    • (1989) Ann Intern J Med , vol.111 , pp. 355-361
    • Hui, S.L.1    Slemenda, C.W.2    Johnston, C.C.3
  • 11
    • 0027525577 scopus 로고
    • Long-term fracture prediction by bone mineral assessed at different skeletal sites
    • Melton LJ, Atkinson EJ, O'Fallon WM, et al. Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res. 1993;8:1227-1233.
    • (1993) J Bone Miner Res , vol.8 , pp. 1227-1233
    • Melton, L.J.1    Atkinson, E.J.2    O'Fallon, W.M.3
  • 12
    • 0023902418 scopus 로고
    • Age and bone mass as predictors of fracture in prospective study
    • Hui SL, Slemenda CW, Johnston CC. Age and bone mass as predictors of fracture in prospective study. J Clin Invest. 1988;81:1804-1809.
    • (1988) J Clin Invest , vol.81 , pp. 1804-1809
    • Hui, S.L.1    Slemenda, C.W.2    Johnston, C.C.3
  • 13
    • 84970843849 scopus 로고
    • Bone densitometry in clinical practise
    • Compston JE, Cooper C, Kanis JA. Bone densitometry in clinical practise. Br J Med J. 1995;310:1507-1510.
    • (1995) Br J Med J , vol.310 , pp. 1507-1510
    • Compston, J.E.1    Cooper, C.2    Kanis, J.A.3
  • 14
    • 0026232676 scopus 로고
    • Bisphosphonates and vertebral fracture: An epidemiological perspective
    • Cooper C, Fogelman I, Melton LJ. Bisphosphonates and vertebral fracture: an epidemiological perspective. Osteoporosis Int. 1991;2:1-4.
    • (1991) Osteoporosis Int , vol.2 , pp. 1-4
    • Cooper, C.1    Fogelman, I.2    Melton, L.J.3
  • 15
    • 0025366467 scopus 로고
    • Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis
    • Storm T, Thamsborg G, Steiniche T, et al. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. NEJM. 1990;322:1265-1271.
    • (1990) NEJM , vol.322 , pp. 1265-1271
    • Storm, T.1    Thamsborg, G.2    Steiniche, T.3
  • 17
    • 0026579492 scopus 로고
    • Future prospects for hormone replacement therapy
    • Reeve J. Future prospects for hormone replacement therapy. Br J Med Bull. 1992;48:458-468.
    • (1992) Br J Med Bull , vol.48 , pp. 458-468
    • Reeve, J.1
  • 18
    • 0029131870 scopus 로고
    • Estrogen therapy for postmenopausal symptoms and prevention of osteoporosis
    • Sagraves R. Estrogen therapy for postmenopausal symptoms and prevention of osteoporosis. J Clin Pharm. 1995;35:2-10.
    • (1995) J Clin Pharm , vol.35 , pp. 2-10
    • Sagraves, R.1
  • 19
    • 0028086440 scopus 로고
    • Estrogen replacement therapy in older women: Comparisons between Alzheimer's disease cases and nondemented control subjects
    • Henderson VW, Paganini-Hill A, Emanuel CK, et al. Estrogen replacement therapy in older women: comparisons between Alzheimer's disease cases and nondemented control subjects. Arch Neurol. 1994;51:896-900.
    • (1994) Arch Neurol , vol.51 , pp. 896-900
    • Henderson, V.W.1    Paganini-Hill, A.2    Emanuel, C.K.3
  • 20
    • 0027266756 scopus 로고
    • Hormone replacement therapy and risk of breast cancer: Results from epidemiologic studies
    • Colditz GA, Egan KM, Stampfer MJ. Hormone replacement therapy and risk of breast cancer: results from epidemiologic studies. Am J Obstet Gynecol. 1993;168:1473-1480.
    • (1993) Am J Obstet Gynecol , vol.168 , pp. 1473-1480
    • Colditz, G.A.1    Egan, K.M.2    Stampfer, M.J.3
  • 21
    • 0028568666 scopus 로고
    • Major issues regarding estrogen replacement therapy in postmenopausal women
    • Bilezikian JP. Major issues regarding estrogen replacement therapy in postmenopausal women. J Women's Health. 1994;3:273-282.
    • (1994) J Women's Health , vol.3 , pp. 273-282
    • Bilezikian, J.P.1
  • 22
    • 0029071008 scopus 로고
    • Hormone-replacement therapy - Breast versus heart versus bone
    • Davidson NE. Hormone-replacement therapy - breast versus heart versus bone. NEJM. 1995;332:1638-1639.
    • (1995) NEJM , vol.332 , pp. 1638-1639
    • Davidson, N.E.1
  • 23
    • 0030279060 scopus 로고    scopus 로고
    • Therapeutic controversy, estrogen replacement in menopause
    • Lindsay R, Bush TL, Grady D, et al. Therapeutic controversy, estrogen replacement in menopause. J Clin Endo & Met. 1996;81:3829-3838.
    • (1996) J Clin Endo & Met , vol.81 , pp. 3829-3838
    • Lindsay, R.1    Bush, T.L.2    Grady, D.3
  • 25
    • 0000122687 scopus 로고    scopus 로고
    • Changes in BMD substantially underestimate the anti-fracture effects of alendronate and other antiresorptive drugs
    • Cummings SR, Black DM, Vogt TM. Changes in BMD substantially underestimate the anti-fracture effects of alendronate and other antiresorptive drugs. J Bone Miner Res. 1996;11:Suppl 1:S102.
    • (1996) J Bone Miner Res , vol.11 , Issue.1 SUPPL.
    • Cummings, S.R.1    Black, D.M.2    Vogt, T.M.3
  • 26
    • 0026168474 scopus 로고
    • Effect of cyclical therapy with phosphorus and etidronate on axial bone mineral density in postmenopausal osteoporotic women
    • Miller PD, Neal BJ, McIntyre DO, et al. Effect of cyclical therapy with phosphorus and etidronate on axial bone mineral density in postmenopausal osteoporotic women. Osteoporosis Int. 1991;1:171-176.
    • (1991) Osteoporosis Int , vol.1 , pp. 171-176
    • Miller, P.D.1    Neal, B.J.2    McIntyre, D.O.3
  • 27
    • 0028963682 scopus 로고
    • Risk factors for hip fracture in white women. Study of osteoporotic fractures research group
    • Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. Study of osteoporotic fractures research group. NEJM. 1995;767-773.
    • (1995) NEJM , pp. 767-773
    • Cummings, S.R.1    Nevitt, M.C.2    Browner, W.S.3
  • 28
    • 0026603713 scopus 로고
    • Rates of change in bone mineral density of the spine, heel, femoral neck, and radius in healthy postmenopausal women
    • Harris S, Dawson-Hughes B. Rates of change in bone mineral density of the spine, heel, femoral neck, and radius in healthy postmenopausal women. Bone Miner. 1992;17:87-95.
    • (1992) Bone Miner , vol.17 , pp. 87-95
    • Harris, S.1    Dawson-Hughes, B.2
  • 29
    • 0029152138 scopus 로고
    • Effect of menopause on femoral and vertebral bone loss
    • Pouilles JM, Tremollieres F, Ribot C. Effect of menopause on femoral and vertebral bone loss. J Bone Min Res. 1995;10:1531-1536.
    • (1995) J Bone Min Res , vol.10 , pp. 1531-1536
    • Pouilles, J.M.1    Tremollieres, F.2    Ribot, C.3
  • 30
    • 25744477916 scopus 로고
    • Bone marker changes in etidronate or estrogen treated postmenopausal women are similar
    • Sacco-Gibson N, Lowry C, Smith J, et al. Bone marker changes in etidronate or estrogen treated postmenopausal women are similar. J Bone Miner Res. 1995;10(suppl):S351.
    • (1995) J Bone Miner Res , vol.10 , Issue.SUPPL.
    • Sacco-Gibson, N.1    Lowry, C.2    Smith, J.3
  • 31
    • 0028606037 scopus 로고
    • Pamidronate: An unrecognized problem in gastrointestinal tolerability
    • Lufkin EG, Argueta R, Whitaker MD, et al. Pamidronate: an unrecognized problem in gastrointestinal tolerability. Osteoporosis Int. 1994;4:320-322.
    • (1994) Osteoporosis Int , vol.4 , pp. 320-322
    • Lufkin, E.G.1    Argueta, R.2    Whitaker, M.D.3
  • 32
    • 0010496839 scopus 로고    scopus 로고
    • Esophagitis associated with the use of alendronate
    • De Groen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. NEJM. 1996;335:1016-1021.
    • (1996) NEJM , vol.335 , pp. 1016-1021
    • De Groen, P.C.1    Lubbe, D.F.2    Hirsch, L.J.3
  • 33
    • 0029840033 scopus 로고    scopus 로고
    • "Pill Esophagitis" - The case of alendronate
    • Castell DO. "Pill Esophagitis" - the case of alendronate. NEJM. 1996;335:1058-1059.
    • (1996) NEJM , vol.335 , pp. 1058-1059
    • Castell, D.O.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.